Plazomicin sulfate

Plazomicin sulfate is an aminoglycoside antibiotic developed by Achaogen. It is used for the treatment of complicated urinary tract infections (cUTIs), including pyelonephritis. Plazomicin sulfate was approved by the Food and Drug Administration (FDA) in June 2018.

History

Plazomicin sulfate was developed by Achaogen, a biopharmaceutical company based in South San Francisco, California. The development of plazomicin sulfate was part of Achaogen's efforts to combat antibiotic resistance, a growing global health concern. The FDA approved plazomicin sulfate in June 2018.

Mechanism of Action

Plazomicin sulfate works by binding to the bacterial 30S ribosomal subunit, inhibiting protein synthesis and thus killing the bacteria. It is particularly effective against Enterobacteriaceae, a family of bacteria that includes Escherichia coli and Klebsiella pneumoniae.

Clinical Use

Plazomicin sulfate is used for the treatment of complicated urinary tract infections (cUTIs), including pyelonephritis. It is administered intravenously.

Side Effects

Common side effects of plazomicin sulfate include nausea, diarrhea, headache, and hypotension. Serious side effects can include nephrotoxicity and ototoxicity, which can lead to kidney damage and hearing loss, respectively.

See Also

• Aminoglycoside
• Antibiotic resistance
• Urinary tract infection